Abstracts tagged "diagnosis and polymyositis/dermatomyositis (PM/DM)"

Abstract Number: 1938 • 2012 ACR/ARHP Annual Meeting
A New Enzyme-Linked Immunosorbent Assay System for Detecting Autoantibodies to Aminoacyl-tRNA Synthetases: Clinical Usefulness in Myositis and Interstitial Pneumonia
Ran Nakashima¹, Yoshitaka Imura², Minae Seto³, Akihiro Murakami³, Yuji Hosono⁴, Kizuku Watanabe⁵, Tomohiro Handa⁵, Michiaki Mishima⁵, Michito Hirakata⁶, Tsutomu Takeuchi⁷, Keishi Fujio⁸, Kazuhiko Yamamoto⁹, Hitoshi Kohsaka¹⁰, Yoshinari Takasaki¹¹, Noriyuki Enomoto¹², Kingo Chida¹², Toshihiro Nukiwa¹³ and Tsuneyo Mimori¹, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Medical & Biological Laboratories Co., Ltd., Ina, Japan, ⁴Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁵Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Kyoto, Japan, ⁶Internal Medicine, Keio University, Tokyo, Japan, ⁷Keio University School of Medicine, Tokyo, Japan, ⁸Department of Allergy and Rheumatology, The University of Tokyo, Tokyo, Japan, ⁹Department of Allergy & Rheumatology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, ¹⁰Department of Medicine and Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan, ¹¹Division of Rheumatology, Department of Internal Medicine, Juntendo University, Tokyo, Japan, ¹²Hamamatsu University School of Medicine, Hamamatsu, Japan, ¹³Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan

Background/Purpose: Autoantibodies to aminoacyl-tRNA synthetases (ARS) are the most frequent myositis-specific antibodies and they are useful in the diagnosis and management of polymyositis (PM)/ dermatomyositis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].